Your session is about to expire
← Back to Search
Secukinumab for Giant Cell Arteritis
Study Summary
This trial is testing a new drug to see if it's effective and safe for people with a disease that causes inflammation in the arteries.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 91 Patients • NCT02690701Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of chronic or recurrent infections, including tuberculosis.You cannot have an MRI/MRA imaging sub-study due to specific health reasons.I can understand and follow the study's requirements.I have not taken specific medications recently.I have a history of serious liver disease or damage.I have not received any live vaccines recently.My condition is getting worse and not under control.I have not lost or donated more than 400 mL of blood in the last 8 weeks.I am a man or a woman not pregnant or breastfeeding, and I am 50 years old or older.I was diagnosed with GCA recently and meet all the specific criteria.I have been diagnosed with new or relapsing Giant Cell Arteritis.I have a history of liver disease, heart issues, blood vessel inflammation, or ongoing inflammatory diseases.My current condition can be managed with a specific dose of prednisone.You have unusual blood counts or ongoing infections.I do not have uncontrolled high blood pressure, heart failure, or diabetes.I am a woman who can have children and am not using birth control.I have been treated with specific biologic drugs before.I have been diagnosed with HIV, hepatitis B, or hepatitis C.I have not had cancer or lymphoproliferative disease in the last 5 years.I am taking MTX (up to 25 mg/week) and can follow specific instructions for it.
- Group 1: Secukinumab 300 mg
- Group 2: Placebo
- Group 3: Secukinumab 150 mg
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you tell me how many medical facilities are involved in this research project?
"This study is being conducted in 16 hospitals, with sites in cities such as Detroit, Los Angeles, Sherbrooke and 14 additional locations. If you are selected to participate, it would be ideal if you could choose a site near you to limit travel difficulties."
Are there any empty slots in this trial that a patient could fill?
"Yes, this trial is still open and recruiting patients. According to the clinicaltrials.gov website, the study was first posted on October 6th, 2021 and last updated on November 10th, 2022."
How many people are taking part in this research project at most?
"That is correct, the online clinicaltrials.gov registry shows that this research project is open for recruitment and has been since October 6th, 2021. The 349 patients will be spread out across 16 hospitals or clinics."
For what medical reasons is Secukinumab 300 mg usually prescribed?
"The secukinumab 300 mg dosage is a standard intervention for ankylosing spondylitis, but can also help patients suffering from psoriatic arthritis, enthesitis related arthritis (era), and severe plaque psoriasis."
Does Secukinumab 300 mg have any harmful side effects for people?
"Previous clinical trials have yielded some data supporting secukinumab's efficacy and multiple rounds of testing have shown that it is a safe medication. Therefore, our team has given it a score of 3."
Is Secukinumab 300 mg a new medication?
"28 clinical trials for Secukinumab 300 mg are currently underway with 13 of them in Phase 3. The study locations for Secukinumab 300 mg include Brest and Buenos Aires among other cities."
Share this study with friends
Copy Link
Messenger